Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SDGR Stock Forecast 2026-2027
$14.38
Current Price
$1.07B
Market Cap
Buy 6
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SDGR Price Targets
+108.6%
To High Target of $30.00
+39.1%
To Median Target of $20.00
-9.6%
To Low Target of $13.00
SDGR Price Momentum
-5.4%
1 Week Change
+10.8%
1 Month Change
-41.6%
1 Year Change
-19.6%
Year-to-Date Change
-48.0%
From 52W High of $27.63
+31.4%
From 52W Low of $10.95
📊 TOP ANALYST CALLS
Did SDGR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Schrodinger is one of their latest high-conviction picks.
Latest SDGR Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, SDGR has a bullish consensus with a median price target of $20.00 (ranging from $13.00 to $30.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $14.38, the median forecast implies a 39.1% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SDGR Analyst Ratings
6
Buy
2
Hold
0
Sell
SDGR Price Target Range
Low
$13.00
Average
$20.00
High
$30.00
Current: $14.38
Latest SDGR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SDGR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Vikram Malhorta | Equal-Weight | Maintains | $17.00 |
| Apr 8, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Mar 17, 2026 | UBS | Neutral | Maintains | $N/A | |
| Jan 8, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Jan 8, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Jan 7, 2026 | UBS | Neutral | Initiates | $N/A | |
| Dec 15, 2025 | B of A Securities | Buy | Upgrade | $N/A | |
| Oct 8, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Sep 30, 2025 | Goldman Sachs | Neutral | Initiates | $N/A | |
| Aug 18, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Aug 15, 2025 | Citigroup | Neutral | Downgrade | $N/A | |
| Aug 14, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Jul 14, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Apr 16, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Feb 27, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jan 24, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Nov 13, 2024 | BMO Capital | Outperform | Maintains | $N/A | |
| Oct 17, 2024 | BMO Capital | Outperform | Maintains | $N/A | |
| Aug 21, 2024 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Jul 11, 2024 | Keybanc | Overweight | Maintains | $N/A |
Schrödinger, Inc. (SDGR) Competitors
The following stocks are similar to Schrodinger based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Schrödinger, Inc. (SDGR) Financial Data
Schrödinger, Inc. has a market capitalization of $1.07B with a P/E ratio of 44.4x. The company generates $254.90M in trailing twelve-month revenue with a -40.6% profit margin.
Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of -83.3% and return on equity of -30.1%.
Valuation Metrics
Market Cap
$1.07B
Enterprise Value
$782.53M
P/E Ratio
44.4x
PEG Ratio
-36.4x
Price/Sales
4.2x
Growth & Margins
Revenue Growth (YoY)
-1.6%
Gross Margin
+50.4%
Operating Margin
-83.3%
Net Margin
-40.6%
EPS Growth
-1.6%
Financial Health
Cash/Price Ratio
+37.1%
Current Ratio
2.7x
Debt/Equity
34.1x
ROE
-30.1%
ROA
-15.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Schrödinger, Inc. (SDGR) Business Model
About Schrödinger, Inc.
What They Do
Develops a computational platform for drug discovery.
Business Model
The company operates through two segments: Software and Drug Discovery. It generates revenue by providing advanced computational tools to biopharmaceutical and biotechnology companies, enhancing their molecular discovery processes. Additionally, it develops preclinical and clinical drug candidates while forming collaborations with notable partners to target specific therapeutic areas.
Additional Information
Founded in 1990 and based in New York, the company leverages computational chemistry and AI-driven simulations to accelerate innovation in drug design and material applications, supporting research from target identification to clinical validation.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
891
CEO
Dr. Ramy Farid Ph.D.
Country
United States
IPO Year
2020
Website
www.schrodinger.comSchrödinger, Inc. (SDGR) Latest News & Analysis
Latest News
Quick Summary
Schrödinger, Inc. granted stock options for 1,875 shares and RSUs for 18,766 shares to newly hired employees on May 18, 2026, under its 2021 Inducement Equity Incentive Plan.
Why It Matters
New equity grants can signal growth and talent acquisition, suggesting potential for future company performance and stock value increase, impacting investor sentiment and stock price.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
In 2026, healthcare AI stocks have declined significantly, with losses ranging from 30% to 65% year-to-date, despite ongoing maturation of their platforms.
Why It Matters
Healthcare AI stocks are significantly declining despite technological progress, indicating potential undervaluation or market skepticism, which could create buying opportunities or signal caution.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
23 days ago
Quick Summary
Schrödinger, Inc. (SDGR) presented at the Bank of America Global Healthcare Conference 2026, sharing insights relevant to investors in the healthcare sector.
Why It Matters
Schrödinger's presentation at a major healthcare conference signals potential insights into its pipeline and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Schrödinger, Inc. (SDGR) held its Q1 2026 earnings call, discussing financial performance and updates. Detailed results and insights were shared during the call.
Why It Matters
Schrödinger's Q1 2026 earnings reveal financial performance and strategic direction, impacting stock valuation and investor confidence in the company's growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Schrödinger, Inc. reported its financial results for Q1 2026, ending March 31. Detailed results are available in the full announcement.
Why It Matters
Quarterly financial results provide insights into Schrödinger's performance, impacting stock valuation and investor sentiment regarding its future growth and profitability.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Schrodinger, Inc. (SDGR) reported a quarterly loss of $0.81 per share, exceeding the Zacks estimate of a $0.56 loss, and compared to a loss of $0.82 per share a year prior.
Why It Matters
Schrodinger's larger-than-expected quarterly loss signals potential operational challenges, which may affect investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About SDGR Stock
What is Schrödinger, Inc.'s (SDGR) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Schrödinger, Inc. (SDGR) has a median price target of $20.00. The highest price target is $30.00 and the lowest is $13.00.
Is SDGR stock a good investment in 2026?
According to current analyst ratings, SDGR has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SDGR stock?
Wall Street analysts predict SDGR stock could reach $20.00 in the next 12 months. This represents a 39.1% increase from the current price of $14.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Schrödinger, Inc.'s business model?
The company operates through two segments: Software and Drug Discovery. It generates revenue by providing advanced computational tools to biopharmaceutical and biotechnology companies, enhancing their molecular discovery processes. Additionally, it develops preclinical and clinical drug candidates while forming collaborations with notable partners to target specific therapeutic areas.
What is the highest forecasted price for SDGR Schrödinger, Inc.?
The highest price target for SDGR is $30.00 from at , which represents a 108.6% increase from the current price of $14.38.
What is the lowest forecasted price for SDGR Schrödinger, Inc.?
The lowest price target for SDGR is $13.00 from at , which represents a -9.6% decrease from the current price of $14.38.
What is the overall SDGR consensus from analysts for Schrödinger, Inc.?
The overall analyst consensus for SDGR is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are SDGR stock price projections?
Stock price projections, including those for Schrödinger, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 11:20 AM UTC